Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q12934

UPID:
BFSP1_HUMAN

ALTERNATIVE NAMES:
Beaded filament structural protein 1; Lens fiber cell beaded-filament structural protein CP 115; Lens intermediate filament-like heavy

ALTERNATIVE UPACC:
Q12934; F5H0G1; O43595; O76034; O95676; Q8IVZ6; Q9HBX4

BACKGROUND:
The protein Filensin, with alternative names such as Lens fiber cell beaded-filament structural protein CP 115, is integral to lens intermediate filament formation alongside BFSP1, BFSP2, and CRYAA. This complex is crucial for maintaining lens transparency and eye health (PubMed:28935373). Filensin's role extends to adjusting MIP water permeability through calcium regulation, underscoring its multifunctionality in the eye lens (PubMed:30790544).

THERAPEUTIC SIGNIFICANCE:
Linked to Cataract 33, multiple types, Filensin's genetic variants underscore its clinical significance. The disease manifests as juvenile-onset lens opacities, impacting vision. Exploring Filensin's functions offers a promising avenue for developing novel cataract therapies, highlighting the protein's therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.